Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ketamine is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist, which is being evaluated as a potential treatment for pain, mental health, and neurological disorders.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Ketamine-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Ketamine is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist, which is being evaluated as a potential treatment for pain, mental health, and neurological disorders.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Ketamine-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
Ketarx (ketamine hydrochloride), is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant in patients with parkinson’s Disease.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Ketarx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
Ketarx™ (ketamine hydrochloride), is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant in patients with parkinson’s Disease.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Ketarx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
Ketarx™ (ketamine hydrochloride), is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant in patients with Parkinson’s Disease.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Ketarx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
Sairiyo will use the net proceeds to advance developments of cepharanthine, for cancer and infectious diseases, and DMT PharmaPatch (N,N-dimethyltryptamine) as a potential treatment for ocular disease and neuropsychiatric conditions.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: PharmaPatch
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Sairiyo Therapeutics
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Financing July 18, 2023
Details:
Ketarx™ (ketamine hydrochloride), is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant in patients with parkinson’s Disease.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Ketarx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Under the collaboration, PharmaTher will be responsible for regulatory, manufacturing and supply of Ketarx (ketamine hydrochloride), an FDA-approved NMDA receptor-modulating drug, and Vitruvias will be responsible for the marketing, sales, and distribution in the U.S. market.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Ketarx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vitruvias Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 20, 2023
Details:
Ketarx™ (ketamine hydrochloride), is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant in patients with parkinson’s Disease.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Ketarx
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Ketarx™(ketamine hydrochloride), is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Ketarx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023